Expression Pathology Nabs $6.5M Investment from Abraxis to Develop Cancer Drug-Response Dxs

The firm also said that it and NextGen Sciences have developed a protein biomarker assay method that can provide rapid, reproducible, quantitative measurement of protein expression in formalin-fixed, paraffin-embedded tissue.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories